Please login to the form below

Not currently logged in
Email:
Password:

Cerenis appoints Dr John Paolini as chief medical officer

He will be responsible for the strategic planning and execution of the biopharmaceutical company's clinical trials

Dr John Paolini has joined biopharmaceutical company Cerenis as chief medical officer.

Dr Paolini comes to the Toulouse, France and Ann Arbor, US-based company with 15 years clinical and research experience, notably at Merck & Co and Bayer Healthcare Pharmaceuticals.

At Cerenis he will be responsible for the strategic planning and execution of the clinical trials for the company's portfolio of novel cardiovascular therapies, including lead product CER-001, which is currently being studied for acute coronary syndrome.

“The appointment of Dr Paolini comes at a crucial time in our development, with our lead drug candidate, CER-001 in phase II; this product addresses a significant unmet medical need and represents a multibillion dollar opportunity,” said Jean-Louis Dasseux, CEO of Cerenis.

29th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics